NCT04462198View on ClinicalTrials.gov

Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

June 17, 2021

Study Completion Date

June 17, 2021

Conditions
Sensorineural Hearing Loss
Interventions
DRUG

PIPE-505

Intratympanic injection

DRUG

Placebo

Intratympanic injection

Trial Locations (8)

27103

Piedmont Ear Nose Throat and Associates, Winston-Salem

28210

Charlotte Eye Ear Nose Throat Associates, Charlotte

33487

ENT and Allergy Associates of Florida, Boca Raton

40220

Advanced ENT & Allergy, Louisville

47150

Advanced ENT & Allergy, New Albany

66160

University of Kansas; Dept of Otolaryngology Head & Neck Surgery, Kansas City

84790

Chrysalis Clinical Research, St. George

90503

Breathe Clear Institute, Torrance

Sponsors
All Listed Sponsors
lead

Contineum Therapeutics

INDUSTRY